Related Experiment Video

Updated: Oct 3, 2025

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.7K

Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer

Ana Maria Montagut1, Marc Armengol2, Gema Gorjón de Pablo1

  • 1Grup de Química Farmacèutica, IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.

Seminars in Cell & Developmental Biology
|February 21, 2022
PubMed

Insights

Ubiquitination, a key protein regulator, is crucial for cellular processes and implicated in cancer. This review highlights recent advances in ubiquitin-targeting therapies, focusing on E1 and E3 modulators for drug discovery.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Ubiquitination is a vital post-translational modification regulating protein degradation and cellular functions.
  • Dysregulation of the ubiquitin system is linked to cancer and other diseases.
  • The ubiquitin system is a validated target for drug development, with existing approved therapies.

Purpose of the Study:

  • To review recent breakthroughs in ubiquitin-targeting therapies over the past decade.
  • To focus on E1 and E3 enzyme modulators.
  • To discuss challenges and chemical strategies for identifying new therapeutic targets in the ubiquitin machinery.

Main Methods:

  • Literature review of recent scientific discoveries.
  • Analysis of crystallographic structures for target identification.
  • Exploration of chemical approaches for drug development.

Main Results:

  • Significant progress has been made in developing ubiquitin-targeting therapies.
  • E1 and E3 modulators represent key areas of focus in recent drug discovery efforts.
  • Crystallographic data offers insights into targeting the complex ubiquitin machinery.

Conclusions:

  • Ubiquitin-modulating therapies hold significant promise for treating various diseases, particularly cancer.
  • Overcoming challenges in target identification is crucial for advancing ubiquitin-based drug discovery.
  • Continued exploration of chemical strategies is essential for realizing the full therapeutic potential of the ubiquitin system.
Keywords:
CancerClinical trialDeubiquitinasePreclinical screeningStructure-based drug designUbiquitin ligase

More Related Videos

Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases06:30

Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases

Published on: August 27, 2021

3.3K
In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones11:36

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones

Published on: July 25, 2019

11.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
7.6K
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.8K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K